Abstract

TENELIGLIPTIN: MANAGEMENT OF TYPE 2 DIABETES MELLITUS

Satish S. and Jayasree B.*

Abstract

The prevalence of type 2 diabetes has been rapidly increased worldwide, particularly in Asian countries.Teneligliptin, a third generation DPP-4 inhibitor exhibits unique ―j-shaped‖ structure with ―anchor-lock domain‖ mechanism which provides potent and long duration of action, it acts like an insulin/glucagon modulator controlling blood glucose and it improves the β-cell parameter. Teneligliptin should be used during pregnancy only if the potential benefit correlate with the potential risk to the foetus. Safe use of teneligliptin during pregnancy has not been establishes. Teneligliptin should be avoided by breastfeeding mother, the transition to milk is reported in the laboratory animals. Teneligliptin should be used during pregnancy only if the potential benefit correlate with the potential risk to the foetus. Safe use of teneligliptin during pregnancy has not been establishes. It should be cautiously given to patients with advanced liver failure, congestive heart failure (NYHA category III-IV), pituitary insufficiency, poor nutritional state starvation, irregular dietary intake, debilitating condition, intensive muscle movement, excessive alcohol intake, history of abdominal surgery, history of bowel obstruction, arrhythmia, severe bradycardia or its history, congestive heart failure, low serum potassium, congenital prolonged QT syndrome, history of Torsades de pointes and patients using antiarrhythmic drugs and insulin secretagogue(risk of hypoglycaemia).

Keywords: .